A new trading day began on Friday, with Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) stock price up 6.95% from the previous day of trading, before settling in for the closing price of $17.85. ARCT’s price has ranged from $14.93 to $45.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 310.16%. Meanwhile, its annual earnings per share averaged -144.71%. With a float of $24.58 million, this company’s outstanding shares have now reached $27.08 million.
The extent of productivity of a business whose workforce counts for 180 workers is very important to gauge. In terms of profitability, gross margin is 104.5%, operating margin of -37.74%, and the pretax margin is -40.69%.
Arcturus Therapeutics Holdings Inc (ARCT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcturus Therapeutics Holdings Inc is 9.27%, while institutional ownership is 88.47%. The most recent insider transaction that took place on Oct 15 ’24, was worth 249,121. In this transaction Chief Scientific Officer & COO of this company sold 12,000 shares at a rate of $20.76, taking the stock ownership to the 435,334 shares. Before that another transaction happened on Oct 15 ’24, when Company’s Officer proposed sale 12,000 for $20.76, making the entire transaction worth $249,121.
Arcturus Therapeutics Holdings Inc (ARCT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -144.71% per share during the next fiscal year.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Here are Arcturus Therapeutics Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.21, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -1.98 in one year’s time.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
The latest stats from [Arcturus Therapeutics Holdings Inc, ARCT] show that its last 5-days average volume of 0.4 million was inferior to 0.47 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 54.83%. Additionally, its Average True Range was 1.39.
During the past 100 days, Arcturus Therapeutics Holdings Inc’s (ARCT) raw stochastic average was set at 37.99%, which indicates a significant decrease from 66.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.05% in the past 14 days, which was higher than the 63.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.65, while its 200-day Moving Average is $25.66. Now, the first resistance to watch is $20.66. This is followed by the second major resistance level at $22.22. The third major resistance level sits at $23.53. If the price goes on to break the first support level at $17.79, it is likely to go to the next support level at $16.48. Assuming the price breaks the second support level, the third support level stands at $14.92.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Key Stats
With a market capitalization of 553.02 million, the company has a total of 27,087K Shares Outstanding. Currently, annual sales are 166,800 K while annual income is -29,730 K. The company’s previous quarter sales were 41,670 K while its latest quarter income was -6,900 K.
